Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR CT

Abstract

Purpose:

To determine the occurrence of physiological significant coronary artery disease (CAD) by coronary CT angiography (CTA) derived fractional flow reserve (FFR_CT) in asymptomatic patients with a new diagnosis (<1 year) of type-2 diabetes mellitus (T2DM).

Methods:

FFR_CT-analysis was performed from standard acquired coronary CTA data sets. The per-patient minimum distal FFR_CT-value (d-FFR_CT) in coronary vessels (diameter ⩾1.8 mm) was registered. The threshold for categorizing FFR_CT-analysis as abnormal was a d-FFR_CT ⩽0.75. Total plaque volume and volumes of calcified plaque, non-calcified plaque, and low-density non-calcified plaque (LD-NCP) were assessed by quantitative plaque analysis.

Results:

Overall, 76 patients; age, mean (SD): 56 (11) years; males, n (%): 49(65), were studied. A total of 57% of patients had plaques. The d-FFR_CT was ⩽0.75 in 12 (16%) patients. The d-FFR_CT, median (IQR), was 0.84 (0.79–0.87). Median (range) d-FFR_CT in patients with d-FFR_CT ⩽0.75 was 0.70 (0.6–0.74). Patients with d-FFR_CT⩽0.75 versus d-FFR_CT >0.75 had numerically higher plaque volumes for all plaques components, although only significant for the LD-NCP component.

Conclusion:

Every sixth asymptomatic patient with a new diagnosis of T2DM has hemodynamic significant CAD as evaluated by FFR_CT. Flow impairment by FFR_CT was associated with coronary plaque characteristics.

Keywords

Type-2 diabetes mellitus coronary computed tomography angiography coronary plaque analysis coronary computed tomography angiography derived fractional flow reserve FFR AutoPlaque

Introduction

Coronary computed tomography angiography (CTA) is recommended as a first line non-invasive test in patients suspected of coronary artery disease (CAD).^1,2 Beyond assessment of diameter stenosis, coronary CTA enables detailed analysis of the burden, and characteristics of coronary plaques.³ Specific plaque properties such as low-density and positive remodeling are associated with an unfavorable clinical outcome,⁴ and it has been demonstrated that adverse plaque features independently of stenosis severity are associated to impaired coronary flow.^5–8 Recently, coronary CTA derived fractional flow reserve (FFR_CT) has emerged for non-invasive physiological evaluation of CAD⁹ before referral to invasive assessment in patients with stable angina pectoris. When validated against invasive FFR,^10–12 the reference standard for decision-making on coronary revascularization,^1,13 FFR_CT demonstrated high diagnostic performance. Moreover, FFR_CT has revealed an enhanced diagnostic sensitivity compared to stress perfusion imaging by single photon emission computerized tomography¹⁴ and cardiac magnetic resonance.¹⁵ FFR_CT testing may change the downstream management of patients,^16,17 and recently, it was demonstrated that the numerical value of FFR_CT is an independent predictor of outcomes.^18–20

The prevalence of CAD is high both at early²¹ and advanced phases of type-2 diabetes mellitus (T2DM).²² A strategy of identifying asymptomatic persons who may benefit from preventive medication has been debated for years.²³ In one prospective randomized study however, screening with traditional coronary CTA failed to demonstrate any incremental prognostic gain in T2DM.²⁴ To the best of our knowledge, no previous study has assessed the hemodynamic significance of CAD in patients with newly diagnosed T2DM.

Consequently, this exploratory study sought to determine the occurrence of physiological significant coronary stenosis by FFR_CT and to relate these estimates with coronary plaque characteristics in asymptomatic patients with newly diagnosed T2DM.

Materials and methods

From March 2014 to August 2016, a total of 213 adult individuals diagnosed with T2DM (hemoglobinA1c >47 mmol/mol and plasma glucose >7 mmol/L) within the last year were identified via general practitioners or outpatient clinics in Region South of Denmark, and invited by letter to participate in this study. A detailed description of patient cohort exclusions criteria and demographic data have been published previously.²¹

This post-hoc study was approved by the Regional Scientific Ethical Committee for Southern Denmark (S- 20140137) and by the Danish data Protection Agency (2008-58-0035), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the participants. The study was registered at ClinicalTrials.gov ID: NCT03022344 and protocol ID: 44110.

Coronary CT angiography

A detailed description of the applied CT acquisition protocol and plaque analysis strategy has been published previously.²¹ In brief, all participants underwent coronary CTA by using a dual-source scanner (SOMATOM Definition Flash; Siemens Healthcare, Forcheim, Germany). Pre-scan oral beta-blockers were administered targeting a heart rate of ⩽60 beats/min. Sublingual nitroglycerin, dose of 0.5 mg, was administered 2 to 4 min before the scan. An initial non-contrast enhanced scan for calcium scoring was performed. One experienced CT cardiologist (more than 10 years of experience in coronary CTA interpretation), blinded to all clinical data, analyzed the CT datasets. Vessels >2 mm in diameter were evaluated and graded visually as follows: normal (0%), non-obstructive stenosis (1–29%), intermediate stenosis (30–69%), obstructive stenosis (⩾70%). Location of stenosis was reported using a 17-segment model.¹²

One trained reader performed plaque analysis using a validated semi-automated software program (AutoPlaque, version 2.0, Cedars-Sinai Medical Center, Los Angeles, CA, USA).^3,25 Total plaque volume and the volumes of calcified plaque (CP), non-calcified plaque (NCP) and low-density NCP (LD-NCP) were assessed. Coronary plaque volumes and characteristics were assessed on a per-patient and a per-vessel basis. All plaque analyses were performed by staff blinded to FFR_CT-results and other patient data.²¹

Medical treatment was not affected by the results of coronary CTA or FFR_CT as these were not available for the treating physicians.

FFR_CT

Standard acquired coronary CTA data sets were transmitted for central FFR_CT analysis (HeartFlow Inc., Redwood City, California).¹² The principles behind FFR_CT computation have previously been described in detail.⁹ FFR_CT was displayed for each point in the coronary tree. Any FFR_CT-value in the major coronary arteries ⩾1.8 mm in diameter, including side branches, was registered.

The per-patient minimum distal FFR_CT-value (d-FFR_CT) was registered. A d-FFR_CT-value ⩽0.75 was indicative of impaired flow.^26,27

Follow-up

Electronic patient journals were used to register major adverse outcomes (all-cause mortality, myocardial infarction and stroke) at follow-up, 4 to 6 years after the initial coronary CTA.

Statistical analysis

Continuous variables are presented as mean values and 95% confidence intervals if normally distributed or median and interquartile range (IQR) if non-normally distributed. Categorical variables are presented as frequencies (n) and percentages. Q-plot was used for testing whether the data were normal distributed. Differences in plaques composition between d-FFR_CT ⩽0.75 versus d-FFR_CT >0.75 were tested using the Wilcoxon rank-sum test. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using Stata software, version 14.0 (StataCorp LLC, College Station, TX, USA).

Results

In total, 115 (54%) patients agreed to participate in this study of whom FFR_CT-analysis was available in 76 patients, Figure 1. Clinical characteristics are presented in Table 1. Stenosis severity according to vessel location (n,%) was as follows: normal (n = 150): left anterior descending artery (LAD), 44 (29%); left circumflex artery (CX), 55 (37%); right coronary artery (RCA), 51 (34%); non-obstructive stenosis (n = 69): LAD, 29 (42%); CX, 17 (25%); RCA, 23 (33%); intermediate stenosis (n = 4): LAD, 1 (25%); CX, 2 (50%); RCA, 1 (25%) and obstructive stenosis (n = 5): LAD, 2 (40%); CX, 2 (40%); RCA, 1 (20%). Mean (SD) heart rate was 59 (7) beats/min and median (IQR) radiation dose was 6.0 (4.7–6.9) mSv.

Figure 1.

Flow diagram.

Table 1.

Clinical characteristics.

Demographics	All	d-FFR_CT ⩽ 0.75	d-FFR_CT > 0.75	p-value
Demographics	n = 76	n = 12	n = 64	p-value
Age, years	56 (11)	56 (11)	55 (11)	0.692
Male	49 (64)	9 (75)	40 (63)	0.406
Risk factors
Body mass index, kg/m²	29.4 (3.8)	30.1 (3.5)	29.3 (3.9)	0.460
Ever smoker	40 (53)	6 (50)	34 (53)	0.842
24 hours blood pressure
Systolic blood pressure, mmHg	131 (12)	136 (8)	129 (12)	0.063
Diastolic blood pressure, mmHg	76 (7)	79 (5)	75 (7)	0.055
Laboratory findings
Total-cholesterol, mmol/L	4.4 (1.0)	4.8 (1.0)	4.3 (1.0)	0.119
LDL-cholesterol, mmol/L	2.5 (0.8)	2.9 (0.7)	2.4 (0.8)	0.040
HDL-cholesterol, mmol/L	1.1 (0.3)	1.1 (0.2)	1.1 (0.3)	0.905
Triglycerides, mmol/L	1.6 (1.3–2.5)	1.8 (1.0–3.0)	1.6 (1.2–2.4)	0.960
HbA1c, mmol/L	45 (42–50)	44 (42–49)	46 (42–50)	0.428
Serum creatinine, umol/L	74 (13)	69 (9)	76 (13)	0.105

d-FFRCT: per-patient minimum distal FFR_CT-value; FFR_CT: coronary computed tomography angiography derived fractional flow reserve; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

Values given as n (%), mean (SD) or median (IQR).

FFR_CT: Plaque relationship

A total of 43 (57%) patients had plaques. Median (IQR) Agatston score was 1 (0–110) U. Thirty-five (46%) patients had an Agatston score of zero. The d-FFR_CT, median (IQR), was 0.84 (0.79–0.87). d-FFR_CT was ⩽0.75 in 12 (16%) patients. Median (range) d-FFR_CT in patients with d-FFR_CT ⩽ 0.75 was 0.70 (0.6–0.74). Patients with d-FFR_CT ⩽ 0.75 versus d-FFR_CT > 0.75 had higher LDL-cholesterol, while no differences between groups regarding BMI, gender, age, smoking habits, blood pressures or HbA1c were observed, Table 1. Patients with d-FFR_CT ⩽ 0.75 versus d-FFR_CT > 0.75 had numerically higher plaque volumes for all plaque components, however the difference was statistical significance only for the LD-NCP component, Table 2.

Table 2.

Patient-specific coronary plaque volumes according to the per-patient minimum distal FFR_CT-value in asymptomatic patients with early stage T2DM.

	d-FFR_CT ⩽ 0.75	d-FFR_CT > 0.75	p-value
	n = 12	n = 64
Plaque volumes, mm ³
NCP	239.8 (3.1–473.3)	3.3 (0–174.6)	0.055
LD-NCP	36.0 (0.1–80.1)	0.2 (0–21.2)	0.038
CP	17.3 (0–167.3)	0.6 (0–26.3)	0.162
TPV	323.1 (3.1–600.5)	6.1 (0–224.2)	0.057

CP: calcified plaque; d-FFR_CT: per-patient minimum distal FFR_CT-value; FFR_CT: coronary computed tomography angiography derived fractional flow reserve; LD-NCP: low-density NCP; NCP: non-calcified plaque, T2DM: type-2 diabetes mellitus; TPV: total plaque volume.

Values given as median (IQR).

Follow-up

Follow-up, mean (SD), was performed 4.8 (0.5) years after the index coronary CTA. One patient died due to alcoholic liver cirrhosis (index coronary CTA: Agatston Score, 36 U; non-obstructive CAD; d-FFR_CT, 0.91) one had a stroke (index coronary CTA: Agatston Score, 109 U; non-obstructive CAD; d-FFR_CT, 0.88) and one patient suffered a myocardial infarction (index coronary CTA: Agatston Score, 1150 U; double-vessel CAD; d-FFR_CT, 0.51), Figure 2. For details on stenosis location and – severity and coronary plaque volumes, see supplemental material.

Figure 2.

Illustration of corresponding coronary CTA, quantitative plaque analysis and FFR_CT.

Discussion

The present study confirms that patients with T2DM have a high burden of CAD already at an early stage of the disease process and demonstrates that every sixth asymptomatic patient with a new diagnosis of T2DM has hemodynamic significant CAD as evaluated by FFR_CT.

This study provides new knowledge by showing that high-risk coronary features such as coronary flow impairment by FFR_CT and adverse plaque characteristics by coronary CTA are frequent in asymptomatic patients with a new diagnosis of T2DM.

Although well-established, coronary CTA is restricted to describe morphological aspects of the atherosclerotic disease process, which has been the basis for evolvement of second-line non-invasive physiological assessment by FFR_CT-based metrics. The d-FFR_CT represents the sum of resistances related to both focal and diffuse atherosclerotic disease along the coronary vessel and thus may be positive even in the absence of focal stenosis and studies in symptomatic populations have demonstrated that adverse plaque characteristics are associated to the presence of coronary pressure loss.^5–8 The present study adds to these findings by demonstrating similar associations in asymptomatic individuals with newly diagnosed T2DM. Of note, a d-FFR_CT ⩽0.75 was associated with higher LD-NCP volumes and higher LDL-cholesterol levels. LD-NCP is considered a surrogate for lipid core plaques,²⁸ and has been associated to unfavorable outcomes.⁴ Several imaging and histopathological studies have demonstrated more profound macrophage infiltration and larger necrotic core of coronary plaques in patients with T2DM compared to patients without diabetes.^29–31 In addition, an abnormal glucose regulation is an important risk factor for coronary plaque progression and is associated with lipid-rich plaques in patients with T2DM compared to non-diabetic subjects.^29,32 High levels of LDL-cholesterol is a well-known risk factor for cardiovascular events and is associated with the presence of high risk coronary plaques.³³ Otaki et al.³⁴ showed that a decrease in LDL-cholesterol is associated with plaque stabilization including a decrease in all components of NCP determined by coronary CTA. Whether LDL lowering can lead to recovery of abnormal flow is at the moment unresolved. However, the observed association between LDL-cholesterol levels and coronary flow impairment in this study and the long-term improvement of invasive fractional flow reserve following LDL lowering by rosuvastatin in a small series of patients with CAD in a small study Hashikata et al.³⁵ are supportive of this hypothesis.

It is well established that conventional clinical risk factors independently predict the development of CAD in T2DM,^36,37 and that multifactorial prevention strategies for late complications are associated with lower rates of micro- and macro-vascular disease.^38,39 The present study adds to these findings by demonstrating that a number of asymptomatic patients with T2DM, already at the time of diagnosis, have adverse coronary plaque characteristics with hemodynamic significance.

Information on the occurrence of morphological and physiological adverse plaque characteristics may be of value in identifying high risk patients with asymptomatic T2DM in whom intensive treatment with, for example, proprotein-konvertase-subtilisin/kexin-type 9 inhibitors, glucagon like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors may be considered. These issues need delineation in future studies.

Limitations

The number of participants in the study was small. Both duration of cholesterol-lowering and antihypertensive medication and changes in cholesterol- and blood pressure levels may have had an impact on coronary flow impairment and plaque phenotype, which could not be accounted for in this study, as these data were not available.

Quantitative assessment of plaque volumes is dependent on several conditions. Recent studies indicated that changes in delineation of plaque boundaries and in discriminative Hounsfield levels improved the correlation between plaque volumes determined by intravascular ultrasound and CT angiography.^40,41

Conclusion

In asymptomatic patients with a new diagnosis of T2DM, coronary flow impairment by FFR_CT is frequently seen and is associated to quantitative estimates of coronary plaque components. Studies are needed to assess the value of performing coronary CTA and selective FFR_CT for therapeutic management decisions in these patients.

Supplemental Material

Supplementary_File – Supplemental material for Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR_CT

Supplemental material, Supplementary_File for Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR_CT by Monija Mrgan, Bjarne Linde Nørgaard, Damini Dey, Jørgen Gram, Michael Hecht Olsen, Jeppe Gram and Niels Peter Rønnow Sand in Diabetes & Vascular Disease Research

Footnotes

Author contributions

MM: designed the study, collected, analyzed and interpreted the data and wrote the report. MM analyzed all CCTA using Autoplaque, did Agatston investigation and FFR analysis; DD: developed the analysis tool and reviewed the manuscript. BN: contributed to the discussion and reviewed the manuscript, JG and JG: designed the study, and edited the manuscript, MHO: conceived and designed the study and edited the manuscript, NPS: conceived and designed the study, collected, analyzed data and contributed to the discussion and reviewed the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Danish Diabetes Academy supported by the Novo Nordisk Foundation; The Faculty of Health Sciences-University of Southern Denmark; Department of Regional Health Research-Center Southwest, Denmark; Edith and Vagn Hedegaard Jensens Foundation, Karola Jørgensens Foundation and Sydvestjysk Cardiologisk Forskningsfund.

Bjarne Linde Nørgaard received unrestricted institutional research grants from Siemens and HeartFlow. Damini Dey is a patent-holder of Autoplaque^© research software, and receives software royalties from Cedars-Sinai Medical Center, Los Angeles, California, USA. The funders had no role in the study design, data collection, data analysis and interpretation, writing of the report, or the decision to submit the article for publication.

ORCID iD

Monija Mrgan

Supplemental material

Supplemental material for this article is available online.

References

Knuuti

Wijns

Saraste

, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407–477.

Skinner

Smeeth

Kendall

, et al. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart 2010; 96(12): 974–978.

Dey

Cheng

Slomka

, et al. Automated 3-dimensional quantification of noncalcified and calcified coronary plaque from coronary CT angiography. J Cardiovasc Comput Tomogr 2009; 3(6): 372–382.

Motoyama

Ito

Sarai

, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol 2015; 66(4): 337–346.

Gaur

Øvrehus

Dey

, et al. Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions. Eur Heart J 2016; 37(15): 1220–1227.

Driessen

Stuijfzand

Raijmakers

, et al. Effect of plaque burden and morphology on myocardial blood flow and fractional flow reserve. J Am Coll Cardiol 2018; 71(5): 499–509.

Ahmadi

Leipsic

Øvrehus

, et al. Lesion-specific and vessel-related determinants of fractional flow reserve beyond coronary artery stenosis. JACC Cardiovasc Imaging 2018; 11(4): 521–530.

Nakazato

Shalev

Doh

J-H

, et al. Aggregate plaque volume by coronary computed tomography angiography is superior and incremental to luminal narrowing for diagnosis of ischemic lesions of intermediate stenosis severity. J Am Coll Cardiol 2013; 62(5): 460–467.

Taylor

Fonte

Min

JK.

Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis. J Am Coll Cardiol 2013; 61(22): 2233–2241.

10.

Driessen

Danad

Stuijfzand

, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. J Am Coll Cardiol 2019; 73(2): 161–173.

11.

Min

Leipsic

Pencina

, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA 2012; 308(12): 1237–1245.

12.

Nørgaard

Leipsic

Gaur

, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (analysis of coronary blood flow using CT angiography: next steps). J Am Coll Cardiol 2014; 63(12): 1145–1155.

13.

Sousa-Uva

Neumann

F-J

Ahlsson

, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55(1): 4–90.

14.

Sand

NPR

Veien

Nielsen

, et al. Prospective comparison of FFR derived from coronary CT angiography with SPECT perfusion imaging in stable coronary artery disease: the ReASSESS study. JACC Cardiovasc Imaging 2018; 11(11): 1640–1650.

15.

Sand

NPR

Nissen

Winther

, et al. Prediction of coronary revascularization in stable angina: comparison of FFR_CT with CMR stress perfusion imaging. JACC Cardiovasc Imaging 2020; 13(4): 994–1004.

16.

Jensen

Bøtker

Mathiassen

, et al. Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. Eur Heart J Cardiovasc Imaging 2018; 19(4): 405–414.

17.

Fairbairn

Nieman

Akasaka

, et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE registry. Eur Heart J 2018; 39(41): 3701–3711.

18.

Patel

Nørgaard

Fairbairn

, et al. 1-Year impact on medical practice and clinical outcomes of FFR_CT: the ADVANCE registry. JACC Cardiovasc Imaging 2020; 13: 97–105.

19.

Ihdayhid

Nørgaard

Gaur

, et al. Prognostic value and risk continuum of noninvasive fractional flow reserve derived from coronary CT angiography. Radiology 2019; 292(2): 343–351.

20.

Nørgaard

Terkelsem

Mathiassen

, et al. Coronary CT angiographic and flow reserve-guided management of patients with stable ischemic heart disease. J Am Coll Cardiol 2018; 72(18): 2123–2134.

21.

Mrgan

Funck

Gaur

, et al. High burden of coronary atherosclerosis in patients with a new diagnosis of type 2 diabetes. Diab Vasc Dis Res 2017; 14(6): 468–476.

22.

Nakanishi

Ceponiene

Osawa

, et al. Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: a propensity-score matching study. Atherosclerosis 2016; 255: 73–79.

23.

Naghavi

Libby

Falk

, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003; 108(14): 1664–1672.

24.

Muhlestein

Lappè

Lima

JAC

, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014; 312(21): 2234–2243.

25.

Dey

Schepis

Marwan

, et al. Automated three-dimensional quantification of noncalcified coronary plaque from coronary CT angiography: comparison with intravascular US. Radiology 2010; 257(2): 516–522.

26.

Doris

Otaki

Arnson

, et al. Non-invasive fractional flow reserve in vessels without severe obstructive stenosis is associated with coronary plaque burden. J Cardiovasc Comput Tomogr 2018; 12(5): 379–384.

27.

Nørgaard

Fairbairn

Safian

, et al. Coronary CT angiography-derived fractional flow reserve testing in patients with stable coronary artery disease: recommendations on interpretation and reporting. Radiol Cardiothorac Imaging 2019; 1(5): e190050.

28.

Ahmadi

Kini

Narula

Discordance between ischemia and stenosis, or PINSS and NIPSS: are we ready for new vocabulary?

JACC Cardiovasc Imaging 2015; 8(1): 111–114.

29.

Amano

Matsubara

Uetani

, et al. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. JACC Cardiovasc Imaging 2008; 1(1): 39–45.

30.

Burke

Kolodgie

Zieske

, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004; 24(7): 1266–1271.

31.

Virmani

Burke

Kolodgie

Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol 2006; 22(Suppl. B): 81B–84B.

32.

Nasu

Tsuchikane, Katoh

, et al. Plaque characterisation by virtual histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 2008; 94(4): 429–433.

33.

Kojima

Maruyoshi

, et al. Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol 2011; 147(3): 371–376.

34.

Otaki

Tamarappoo

Cadet

, et al. Decrease in LDL-C is associated with decrease in all components of noncalcified plaque on coronary CTA. Atherosclerosis 2019; 285: 128–134.

35.

Hashikata

Tojo

Muramatsu

, et al. Lower level of low density lipoprotein cholesterol is associated with a higher increase in the fractional flow reserve in patients with fixed-dose Rosuvastatin. J Atheroscler Thromb 2018; 25(3): 233–243.

36.

Sarwar

Gao

Seshasai

SRK

, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215–2222.

37.

D’Agostino

Sr Grundy

Sullivan

, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286(2): 180–187.

38.

Gaede

Parving

Pedersen

, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353(9153): 617–622.

39.

Gaede

Vedel

Larsen

, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–393.

40.

Matsumoto

Watanabe

Kyo

, et al. Improved evaluation of lipid-rich plaque at coronary CT angiography: head-to-head comparison with intravascular US. Radiol Cardiothorac Imaging 2019; 1(5): e190069.

41.

Matsumoto

Watanabe

Kyo

, et al. Standardized volumetric plaque quantification and characterization from coronary CT angiography: a head-to-head comparison with invasive intravascular ultrasound. Eur Radiol 2019; 29(11): 6129–6139.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR CT

Abstract

Purpose:

Methods:

Results:

Conclusion:

Keywords

Introduction

Materials and methods

Coronary CT angiography

FFRCT

Follow-up

Statistical analysis

Results

FFRCT: Plaque relationship

Follow-up

Discussion

Limitations

Conclusion

Supplemental Material

Supplementary_File – Supplemental material for Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFRCT

Footnotes

Author contributions

Declaration of conflicting interests

Funding

ORCID iD

Supplemental material

References

Supplementary Material

FFR_CT

FFR_CT: Plaque relationship

Supplementary_File – Supplemental material for Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR_CT